Spyre reports positive phase 2 trial results for ulcerative colitis drug

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. ACN
2. SPCX
3. ABBV
4. DFTX
5. BAUFF
6. INTC
7. ICE
8. ELDN
9. KR
10. APGE

Go back to Spyre reports positive phase 2 trial results for ulcerative colitis drug
(NASDAQ: SYRE) Delayed: 88.34 --0 (-0%)
Previous Close $88.34    52 Week High $ 
Open $88.34    52 Week Low $ 
Day High $88.34    P/E N/A 
Day Low $88.34    EPS $ 
Volume 26,489